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Methods:  25 
Patients: 26 
Participants were recruited from the Royal Brompton Allergy Clinic or 27 
following placement of an advertisement in the local newspaper. The study was 28 
performed with approval of the ethics committee of the Royal Brompton Hospital and 29 
with the informed consent of the participants. The patients comprised 13 untreated 30 
grass pollen allergic subjects (7 male, mean age 36 yrs (range 24-59 yrs), skin prick 31 
test 47.3±8.0 mm2 (mean±SEM) and nine atopic hayfever sufferers who had 32 
completed two years of grass pollen injection immunotherapy (6 male, mean age 31 33 
yrs (range 22-38 yrs), skin prick test 55.5±6.6 mm2).E1 The nonatopic healthy controls 34 
comprised 5 males and 4 females, mean age 29 yrs (range 24-41 yrs), skin prick tests 35 
negative to a panel of 11 common aeroallergens {Grass pollen, birch pollen, mixed 36 
tree pollen, Dermatophagoides Pteronyssinus, cat, dog, horse, and moulds (Alternaria, 37 
Cladosporium and Aspergillus Fumigatus) and negative (diluent) and positive 38 
(histamine 10 mg/ml) controls} Soluprick ALK Denmark, and no symptoms during 39 
the pollen season. The effects of GP-IT on Foxp3+ cells during the pollen season was 40 
studied in 37 patients who participated in a previously reported randomised controlled 41 
trial E2. Twenty subjects [10 male, median age 32yrs (range 26-36yrs)] received GP-42 
IT and 17 subjects received placebo injections [9 male, median age 34yrs (range 29-43 
34yrs)]. GP-IT Injections (Alutard SQ Phleum Pratense, ALK Abello) or placebo 44 
injections were given during a cluster 4 week updosing phase followed by monthly 45 
maintenance injections (containing 20 mcg major allergen Phleum p5) for 2 years. 46 
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Nasal biopsies were taken at baseline and during the pollen season following 2 years 47 
treatment, as described. E2    48 
A global assessment of seasonal hayfever severity was performed at the end of 49 
the pollen season, in which patients recorded there hayfever severity on a scale of  -3 50 
to +3 compared to previous years or compared to before commencing 51 
immunotherapy.  52 
Skin prick tests and intradermal skin tests were performed using grass pollen 53 
extract (Phleum Pratense, Soluprick, ALK Abello, Denmark). Skin prick tests were 54 
performed on the flexor aspect of the forearm. Intradermal tests were performed using 55 
0.02 ml of diluent containing 10 Biological units (BU)/ml. on the extensor aspect of 56 
the forearm and the early skin response (weal size) at 15 minutes and late swelling 57 
after 24 hours were recorded as previously described E1.   58 
 59 
Biopsy Collection:   60 
Nasal biopsies were collected outside the UK pollen season from October - 61 
March from GP-IT treated patients and untreated hayfever suffers and between June 62 
- August from nonatopic healthy controls. None of the patients were symptomatic or 63 
taking medication at the time of biopsy as their biopsies were taken remote from the 64 
pollen season. Immunotherapy-treated patients had received treatment for at least 2 65 
years and remained on treatment at the time of biopsy, with biopsies being taken 2-4 66 
weeks after the most recent monthly maintenance injection. The effect of seasonal 67 
exposure was examined on biopsies taken at baseline and during the peak pollen 68 
season after treatment. E1 69 
 70 
Immunohistochemistry: 71 
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Six micron, 4% paraformaldehyde fixed cryostat sections were used in the 72 
study. Foxp3 colocalized to CD4 and CD25 T cells, was visualised by double 73 
immunofluorescence using a biotin- streptavidin system. Monoclonal antibodies to 74 
CD4 and CD25 (Dako Cytomation, UK), polyclonal goat anti Foxp3 (Abcam, 75 
Cambridge, UK) for the detection of nuclear Foxp3 and monoclonal antibody to 76 
human IL-10 (Santa Cruz Biotechnology, Santa Cruz, CA) were used to colocalize 77 
Foxp3 and IL-10 in T cell subsets. The method for the detection of IL-10 used in the 78 
present study has been previously validated.E2 T cell subsets were detected by two or 79 
three step staining. FITC- labelled rabbit anti-mouse (2 steps), or rabbit anti-mouse 80 
secondary antibodies (3 steps) (Dako Cytomation) were used for lymphocyte subsets, 81 
and biotinylated anti-goat antibody (Jackson Immunoresearch) for Foxp3 detection. 82 
These were followed by TRITC-swine anti- rabbit Ig (Dako Cytomation) for T cell 83 
subsets (3 steps), and streptavidin-Alexa Fluor 488 (for Foxp3 detection) (Invitrogen, 84 
Paisley, Scotland, UK).E3 Normal goat IgG, mouse IgG1 and IgG2b (Dako 85 
Cytomation) were used as controls for Foxp3, CD4/ CD25 and IL-10 antibodies 86 
respectively.   87 
 88 
Blocking of Foxp3 staining: Foxp3 synthetic peptide was incubated with goat anti- 89 
Foxp3 antibody at a ratio of 30:1. The mixture was incubated at 4oC overnight. The 90 
mixture was then centrifuged for 15 minutes at 10,000g and the supernatant was used 91 
for immunostaining of tonsil sections.    92 
Quantification    93 
Coded sections were counted independently from the clinical protocol and in a 94 
blinded fashion. Positively stained cells were counted immediately beneath the 95 
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epithelium to two grids depth along the whole length of biopsy, and results expressed 96 
as the number of positive cells per square millimetre. On average this involved 97 
counting cells in 8 fields which is equivalent to 0.8mm2 (0.2 – 1.8mm2) of sub-98 
epithelial tissue per biopsy. The sections stained for Foxp3+, CD4+ and CD25+ cells 99 
and dual stained sections for Foxp3+, CD4+ and CD25+ cells and colocalization of 100 
Foxp3 to CD4 and CD25 cells were examined and counted at 400× magnification 101 
with a Nikon Eclipse (E400) fluorescent microscope (Tokyo, Japan) under appropriate 102 
absorption/emission wavelengths (590/617nm for CD4+ & CD25+ cells, TRITC, and 103 
488/519 nm for Foxp3, Alexa Fluor 488). The images were captured using Nikon 104 
Digital Still Camera DXM1200 with Lucia 4.8 software (system for Image processing 105 
and analysis; Prague, Czech Republic).  106 
 107 
Results:  108 
The effect of seasonal grass pollen exposure on Foxp3 expression in the nasal 109 
mucosa is shown in Table 1. Seasonal increases in Foxp3+ cells compared to baseline 110 
were observed in both placebo- and immunotherapy-treated subjects whereas 111 
significant increases in dual positive Foxp3+CD4 cells and Foxp3+CD25+ cells were 112 
observed only in the immunotherapy-treated group. For comparison with the effects 113 
of immunotherapy on seasonal allergic inflammation, previously reported counts for 114 
eosinophils and IL-5 expressing cells E4 are also included along with numbers of 115 
Foxp3 expressing cells in Table 1. Seasonal increases were observed for both 116 
eosinophils and IL-5 mRNA expressing cells in placebo treated patients which were 117 
inhibited after immunotherapy.  118 
 119 
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